Literature DB >> 20041004

Progressive Multifocal Leukoencephalopathy in HIV-Infected Children: A Case Report and Literature Review.

Peninnah Oberdorfer1, Charles H Washington, Kamornwan Katanyuwong, Podjanee Jittamala.   

Abstract

We report a case of a perinatally HIV-infected patient aged 9 years, who presented with right-sided hemiplegia. His initial CD4 T-cell was of 0.21% (4 cells/muL) and plasma HIV RNA virus of 185 976 copies/mL (log 5.27). Plasma and CSF samples were subsequently positive for JCV. Twelve days after the initiation of highly active antiretroviral therapy (HAART), the MRI showed progressive white matter lesions with asymmetrical deep and subcortical white matter lesions over the left frontotemporoparietal region and the right frontal lobe. Immune Reconstitution Inflammatory Syndrome (IRIS) was suspected, and the patient was treated with methylprednisolone. His clinical symptoms worsened and despite therapy the patient deteriorated.

Entities:  

Year:  2009        PMID: 20041004      PMCID: PMC2778135          DOI: 10.1155/2009/348507

Source DB:  PubMed          Journal:  Int J Pediatr        ISSN: 1687-9740


1. Background

Progressive multifocal leukoencephalopathy (PML) is caused by the JC virus (JCV). As a demyelinating disease, PML typically presents with altered mental status, motor deficits, and ataxia, and is associated with immunosuppression, especially human immunodeficiency virus (HIV) [1]. Prevalence of JCV specific antibodies increases rapidly during childhood, but the mode of transmission is unknown [2]. PML is rare in HIV-infected children and even more uncommonly associated to immune reconstitution inflammatory syndrome (IRIS) in children.

2. Case Report

2.1. First Admission

A previously healthy 9-year-old boy (whose mother was recently found to be HIV-positive) presented to the hospital with 1 week of right-sided hemiplegia and right-sided facial palsy. Past medical history included psoriasis, diagnosed 4 years prior. His only HIV exposure was perinatal. On exam the patient weighed 22 kilograms, and vitals signs were within normal limits. He was alert and oriented with a normal level of consciousness and responded appropriately to questions. His speech was slowed and slurred, but this was his baseline according to his mother. He had right-sided facial palsy and right-sided tongue deviation; otherwise cranial nerves were intact. The boy had 3/5 strength in the right upper extremity and 4/5 strength in the right lower extremity. Left-sided strength was 5/5. The patient was able to walk with limited difficulty. Deep tendon reflexes were 2+ and 3+ throughout. Babinski's sign showed dorsiflexion of the right 1st toe. Sensation was intact throughout. The patient also had clusters of 1-2 mm skin colored papules on his forehead and left cheek in addition to diffuse mild psoriatic scaling. Immunizations were up to date. The patient was admitted for a workup of these symptoms. Laboratory studies showed complete blood count: hematocrit 31.6%, hemoglobin 10.5 g/dL, white blood cell count 5000 cells/μL (N 41%, L 35%, E 12%, M 6%, B 1%, atypical L 1%), and 157 000 platelets/μL. HIV-antibody test was positive with a CD4 T-cell 0.21% (4 cells/μL) and plasma HIV RNA virus of 185 976 copies/mL (log 5.27). Tests for Cryptococcus antigen, Toxoplasmosis antigen, Ebstein Barr virus IgG and IgM, Cytomegalovirus IgG and IgM, Hepes Simplex virus polymerase chain reaction (PCR), Japanese encephalitis as well as cultures for tuberculosis and fungi (plasma and cerebrospinal fluid, CSF) were all negative. Plasma and CSF samples were positive for JCV by real time PCR with a plasma RNA level of 226 copies/mL. Three days after admission a brain computerized tomography (CT) scan was performed and showed frond-like hypodense lesion at the left frontal lobe with mild effacement of the left frontal horn of the lateral ventricle. Highly active antiretroviral therapy (HAART) regimen was subsequently started 10 days after admission, consisting of GPOvir-Z (coformulated zidovudine 250 mg, lamivudine 150 mg, and nevirapine 200 mg) [3]. Clinically, the patient deteriorated during the 1st and 2nd weeks of HAART with fever and increased right leg weakness, but immunologic and virologic improvement was seen (CD4 T-cell count 0.8%, 10 cells/μL, and a plasma HIV RNA viral level of 26 532 copies/mL, log 4.42). CT (Figure 1) and brain magnetic resonance imaging (MRI; Figure 2) scans were subsequently performed. The scans showed progressive of white matter lesions with asymmetrical deep and subcortical white matter lesions over the left frontotemporoparietal region and the right frontal lobe. The lesion on the left hemisphere involved internal capsule, lentiform nucleus, thalamus, and genu of corpus callosum and anterior cerebellar hemisphere. There were no enhanced areas after the contrast study.
Figure 1

CT on day 30 of onset of symptoms and 1 week post-HAART initiation.

Figure 2

MRI on day 38 of onset of symptoms and 2 weeks post-HAART initiation.

The patient was discharged 7 weeks after the first admission. Upon discharge he was able to walk with assistance, but was unable to speak.

2.2. Second Admission

The patient was readmitted one day after discharge due to autonomic nervous system dysfunction (nausea, vomiting, and loss of bowel and bladder tone). Deep tendon reflexes were 4+ throughout, and Babinski was positive bilaterally. Continued improvement of immunologic (CD4 T-cell count 2.0%, 30 cells/μL) and virologic (HIV RNA level 3220 copies/mL, log 3.51) measures were seen. Due to progressive neurologic symptoms HAART was ceased. The second MRI (Figure 3) scan was performed and showed a progressive lesion in the same regions as described in the previous MRI, but also found new lesions over the midbrain, pons, and medulla predominantly on the left. The patient was discharged approximately 3 weeks after admission.
Figure 3

2nd MRI, 3 1/2 months after onset of symptoms, 3 days post-HAART cessation.

2.3. Third Admission

The patient was readmitted 1 month later (100 days after onset of symptoms). Immune Reconstitution Inflammatory Syndrome (IRIS) was suspected, and the boy was treated with methylprednisolone (2 mg/kg/day) for 5 days. Despite HAART suspension and administration of steroids, his clinical symptoms worsened. The third MRI (Figure 4) scan showed new lesions in the regions of the right brainstem and right hemisphere with gyral enhancement. The patient's mother refused further treatment, he was discharged home, and he subsequently died 1 year later.
Figure 4

3rd MRI, 4 months after onset of symptoms, 19 days post-HAART cessation.

3. Summary

We report the 2nd case of IRIS associated PML in a perinatally HIV-infected child. Since 1992 there have been reports of 14 HIV-infected children having PML (Table 1) [4-14]. Overall, PML in HIV-infected children has occurred mostly in boys (9/14, 75%), with a median age of 10 years (range: 7–17). Reports have come from Brazil, Hungary, India, Japan, South Africa, Thailand, and USA. Presenting symptoms included: altered speech, hemiplegia, facial palsy, and cerebellar dysfunction. All had significant changes on MRI or CT. Presenting CD4 T-cell counts were low, while viral loads were high. The most common outcome was death.
Table 1

Overview of studies concerning progressive multifocal leukoencephalopathy in HIV-infected children.

AuthorYear reportedSex Age (years)CountryPresentationMRI/CTPrevious HIV- related eventHAART regimenCD4 T-cell % or count (cell/μL)Viral load (copies/mL)Outcome
Baseline Nearest to episode Baseline Nearest to episode
Oberdorfer et al. 2009 M 9 Thailand Right hemiplegia Frond-like hypodense lesion at the left frontal lobe None Initially nothing then AZT, 3TC, NVP 0.21 0.21 185 976 185 976 Dead
Liptai et al. 2007 M 15 1/2 Hungary Dizzy, diplopia, clumsy right hand, unsteady gait Large, nonenhancing lesion of the right cerebellar heimsphere with a slight mass effect None reported Initially AZT, ddl then refused HAART 37 10.5 2900 256 000 Dead
Shah and Chudgar. 2005 F 8 1/2 India Right-sided dystonia, inability to talk, eat, or sit Asymmetrical subcortical, right frontoparietal, left occipitoparietal and left vasal ganglia lesions Generalized tonic clonic seizures and loss of consciousness Initially nothing then AZT, 3TC, EFV, NLF 320 Alive, still has dystonia
Robinson et al. 2004 M 17 USA Dysarthric speech, facial palsy Multiple confluent areas of high signal and fluid attenuated inversion recovery in the corona radiata bilaterally Pneumocystis jiroveci pneumonia Initially AZT, 3TC then d4T, NVP, lopinavir/ ritonavir then included cidofovir 3 3 10–90 000 29 100 Stable, wide-based gait, dysarthria, right-sided tongue deviation
Nuttall et al. 2004 M 12 South Africa Acute cerebellar dysfunction, hemiparesis Nonenhancing low density lesion in the left cerebellar hemisphere Growth failure, chronic lung disease d4T, 3TC, efavirenz 1.08 5.45 96 000 Undetectable Stable, mild cerebellar dysfunction
Inui et al. 1999 M 12 Jaban Left upper extremity weakness White matter lesions of the right frontal, parietal and occipital lobes Candida stomatitis AZT then ritonavir and 3TC added 9.5 7600 Stable, left hemiparesis
Araujo et al. 1997 M 10 Brazil Subacute cerebellar dysfunction, dementia Focal nonenhancing area of low attenuation in the cerebellum None reported
Morriss et al. 1997 M 7 USA Decreased activity, slurred speech, ataxia Confluent, nonenhancing, low density lesion in the right cerebellar white matter, middle cerebellar peduncle and dorsolateral pons Candida esophagitis ddc 0 Death
Whiteman et al.1993 M 10 USA
F 12 USA Increased signal intensity in the basal ganglia and corona radiata bilaterally
Berger et al.1992 F 13 USA Dysarthria, paresthesias of tongue and chin Sinusitis and hyperintense signals in the basal ganglia Oral candidiasis AZT 421 7 Death
M 10 USA Facial palsy Left frontal lobe lesion Pneumocystis jiroveci pneumonia AZT 100 Death
Vandersteenhoven et al. 1992 M 7 USA Decreased activity, left hemiparesis, falling Bilateral confluent abnormal white matter hyperintensity in the region of the right subcortical/ periventricular region None reported Initially nothing then AZT 390 Death
Neuroimaging is an important part of the diagnosis. Multiple bilateral areas of white matter demyelination without contrast enhancement or mass effect are typical findings. For CT imaging these appear hypodense, while on MRI they have either decreased or increased signals depending on the imaging parameters [14-16]. Treatment for PML is based on HAART initiation or optimization, which has shown improved mortality associated with lower HIV RNA plasma viral levels and higher CD4 T-cell count [17-20]. Although rare, casesof PML associated with IRIS occur where there is clinical deteriorationdespite improvement of immunological and virologicalmeasures after the initiation of HAART [21, 22]. This was seen in the case reported here and the other reported case of PML in an HIV-infected child associated with IRIS [10]. Reported in 2004, a 12-year-old African boy developed cerebellar dysfunction and hemiparesis 5 weeks after starting HAART. He was started on prednisone and continued on HAART. He subsequently had immunologic and virologic improvement with full clinical recovery. Estimates from HIV-infected adults with PML associated IRIS range from 9–19%, typically occurring 3–5 weeks after initiation; this is purportedly much less common in children, as it is only sporadically mentioned in the literature [18, 23]. Therapy for PML associated IRIS has included glucocorticoids in addition to HAART interruption, which have been shown to be both beneficial and to be of no benefit in HIV-infected adults with PML [10, 22, 24–26]. Our patient saw further clinical deterioration, despite a trial of these measures unlike the boy in Africa [10]. PML in HIV-infected adolescents has a wide distribution of ages and geography. Despite the cases presented here, there is limited information about this disease in children. Underdiagnosis is likely to both perpetuate this knowledge gap and discourage physicians from identifying this condition. Additionally, in developing countries, such as Thailand, lack of imaging and laboratory data may further hinder diagnosis. Clinicians should then be cognizant of both of this condition and sequelae after HAART, so that prompt diagnosis and treatment can be made. Clear guidelines would be beneficial to clinicians who face these complex patients.
  25 in total

1.  Clinical course and prognostic factors of progressive multifocal leukoencephalopathy in patients treated with highly active antiretroviral therapy.

Authors:  Juan Berenguer; Pilar Miralles; Julio Arrizabalaga; Esteban Ribera; Fernando Dronda; Josu Baraia-Etxaburu; Pere Domingo; Manuel Márquez; Francisco J Rodriguez-Arrondo; Fernando Laguna; Rafael Rubio; José Lacruz Rodrigo; J Mallolas; Verónica de Miguel
Journal:  Clin Infect Dis       Date:  2003-04-02       Impact factor: 9.079

2.  Immune reconstitution inflammatory syndrome in the CNS of HIV-infected patients.

Authors:  A Venkataramana; C A Pardo; J C McArthur; D A Kerr; D N Irani; J W Griffin; P Burger; D S Reich; P A Calabresi; A Nath
Journal:  Neurology       Date:  2006-08-08       Impact factor: 9.910

3.  Prognosis of human immunodeficiency virus infection in children and adolescents.

Authors:  K Krasinski; W Borkowsky; R S Holzman
Journal:  Pediatr Infect Dis J       Date:  1989-04       Impact factor: 2.129

4.  Progressive multifocal leukoencephalopathy in 47 HIV-seropositive patients: neuroimaging with clinical and pathologic correlation.

Authors:  M L Whiteman; M J Post; J R Berger; L G Tate; M D Bell; L P Limonte
Journal:  Radiology       Date:  1993-04       Impact factor: 11.105

5.  Fulminant inflammatory leukoencephalopathy associated with HAART-induced immune restoration in AIDS-related progressive multifocal leukoencephalopathy.

Authors:  Aurélie Vendrely; Boris Bienvenu; Jacques Gasnault; Jean Baptiste Thiebault; Dominique Salmon; Françoise Gray
Journal:  Acta Neuropathol       Date:  2005-03-01       Impact factor: 17.088

6.  Progressive multifocal leukoencephalopathy in a child with acquired immunodeficiency syndrome (AIDS).

Authors:  A P Araujo; H S Pereira; R H Oliveira; A C Frota; J C Esperança; F Duarte
Journal:  Arq Neuropsiquiatr       Date:  1997-03       Impact factor: 1.420

7.  Progressive multifocal leukoencephalopathy after initiation of highly active antiretroviral therapy in a child with advanced human immunodeficiency virus infection: a case of immune reconstitution inflammatory syndrome.

Authors:  James J C Nuttall; Jo M Wilmshurst; Alvin P Ndondo; Jane Yeats; Craig Corcoran; Gregory D Hussey; Brian S Eley
Journal:  Pediatr Infect Dis J       Date:  2004-07       Impact factor: 2.129

8.  A pilot study of cidofovir for progressive multifocal leukoencephalopathy in AIDS.

Authors:  Christina M Marra; Natasa Rajicic; David E Barker; Bruce A Cohen; David Clifford; M Judith Donovan Post; Armando Ruiz; Brian C Bowen; Meei-Li Huang; Jennie Queen-Baker; Janet Andersen; Sue Kelly; Sharon Shriver
Journal:  AIDS       Date:  2002-09-06       Impact factor: 4.177

9.  Progressive multifocal leukoencephalopathy in HIV-1-infected children.

Authors:  J R Berger; G Scott; J Albrecht; A L Belman; C Tornatore; E O Major
Journal:  AIDS       Date:  1992-08       Impact factor: 4.177

10.  Progressive multifocal leukoencephalopathy in an HIV-infected child.

Authors:  Z Liptai; E Papp; P Barsi; I Mihály; E Szalai; J Csomor; Z Jelenik
Journal:  Neuropediatrics       Date:  2007-02       Impact factor: 1.947

View more
  5 in total

Review 1.  Progressive multifocal leukoencephalopathy in pediatric patients: case report and literature review.

Authors:  Hayden Schwenk; Lynn Ramirez-Avila; Shu-Hsien Sheu; Christian Wuthrich; Jeff Waugh; Adam Was; Umberto Degirolami; Sandra Burchett; Igor J Koralnik; Asim Ahmed
Journal:  Pediatr Infect Dis J       Date:  2014-04       Impact factor: 2.129

2.  Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics.

Authors:  George K Siberry; Mark J Abzug; Sharon Nachman; Michael T Brady; Kenneth L Dominguez; Edward Handelsman; Lynne M Mofenson; Steve Nesheim
Journal:  Pediatr Infect Dis J       Date:  2013-11       Impact factor: 2.129

3.  Nuclear factor-kappa B family member RelB inhibits human immunodeficiency virus-1 Tat-induced tumor necrosis factor-alpha production.

Authors:  Michelle Kiebala; Oksana Polesskaya; Zhenqiang Yao; Seth W Perry; Sanjay B Maggirwar
Journal:  PLoS One       Date:  2010-07-29       Impact factor: 3.240

4.  Incidence of opportunistic illness before and after initiation of highly active antiretroviral therapy in children.

Authors:  Steven R Nesheim; Felicia Hardnett; John T Wheeling; George K Siberry; Mary E Paul; Patricia Emmanuel; Beverly Bohannon; Kenneth Dominguez
Journal:  Pediatr Infect Dis J       Date:  2013-10       Impact factor: 2.129

5.  Central nervous system disease with JC virus infection in adults with congenital HIV.

Authors:  Caleb R S McEntire; Kathryn T Fong; Dan Tong Jia; Ellen R Cooper; Anna M Cervantes-Arslanian; Farrah J Mateen; Pria Anand; Kiran T Thakur
Journal:  AIDS       Date:  2021-02-02       Impact factor: 4.632

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.